LEAPS therapeutic vaccines as antigen specific suppressors of inflammation in infectious and autoimmune diseases

Daniel H. Zimmerman, Harold Steiner, Roy Carmabula, Eyal Talor, Ken S. Rosenthal

Research output: Contribution to journalArticle

Abstract

The L.E.A.P.S.™ (Ligand Epitope Antigen Presentation System) technology platform has been used to develop immunoprotective and immunomodulating small peptide vaccines for infectious and autoimmune diseases. Several products are currently in various stages of development, at the pre-clinical stage (in animal challenge efficacy studies). Vaccine peptides can elicit protection of animals from lethal viral (herpes simplex virus [HSV-1] and influenza A) infection or can block the progression of autoimmune diseases (e.g. rheumatoid arthritis as in the collagen induced arthritis (CIA] or experimental autoimmune myocarditis (EAM) models). L.E.A.P.S. technology is a novel T-cell immunization technology that enables the design and synthesis of non-recombinant, proprietary peptide immunogens. Combination of a small peptide that activates the immune system with another small peptide from a disease-related protein, thus a conjugate containing both an Immune Cell Binding Ligand (ICBL) and a disease specific epitope, which allows the L.E.A.P.S. vaccines to activate precursors to differentiate and become more mature cells that can initiate and direct appropriate T cell responses. As such, readily synthesized, defined immunogens can be prepared to different diseases and are likely to elicit protection or therapy as applicable in humans as they are in mice. L.E.A.P.S. vaccines have promise for the treatment of rheumatoid arthritis and other inflammatory diseases and for infections, such as influenza and HSV1. The protective responses are characterized as Th1 immune and immunomodulatory responses with increased IL-12p70 and IFN-γ (Th1 cytokines) but reduced inflammatory cytokines TNF-α, IL-1 and IL-17 (Th2 and Th17 cytokines) and concomitant changes in antibody subtypes. LEAPS immunogens have been used directly in vivo or as ex vivo activators of DC which are then administered to the host.

Original languageEnglish (US)
JournalJournal of Vaccines and Vaccination
Volume3
Issue number5
DOIs
StatePublished - Sep 1 2012
Externally publishedYes

Fingerprint

Autoimmune Diseases
Communicable Diseases
Antigen Presentation
Epitopes
Vaccines
Ligands
Inflammation
Antigens
Subunit Vaccines
Human Herpesvirus 1
Cytokines
Technology
Peptides
Human Influenza
Rheumatoid Arthritis
T-Lymphocytes
Therapeutics
Experimental Arthritis
Interleukin-17
Myocarditis

Keywords

  • Antiviral vaccines
  • Autoimmunity
  • Cytokines
  • Dendritic cell
  • Immune response
  • Mode of action
  • Peptide
  • T cells
  • Vaccines

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Drug Discovery
  • Virology

Cite this

LEAPS therapeutic vaccines as antigen specific suppressors of inflammation in infectious and autoimmune diseases. / Zimmerman, Daniel H.; Steiner, Harold; Carmabula, Roy; Talor, Eyal; Rosenthal, Ken S.

In: Journal of Vaccines and Vaccination, Vol. 3, No. 5, 01.09.2012.

Research output: Contribution to journalArticle

Zimmerman, Daniel H. ; Steiner, Harold ; Carmabula, Roy ; Talor, Eyal ; Rosenthal, Ken S. / LEAPS therapeutic vaccines as antigen specific suppressors of inflammation in infectious and autoimmune diseases. In: Journal of Vaccines and Vaccination. 2012 ; Vol. 3, No. 5.
@article{4b234dcd26624db895e308d24fa875da,
title = "LEAPS therapeutic vaccines as antigen specific suppressors of inflammation in infectious and autoimmune diseases",
abstract = "The L.E.A.P.S.™ (Ligand Epitope Antigen Presentation System) technology platform has been used to develop immunoprotective and immunomodulating small peptide vaccines for infectious and autoimmune diseases. Several products are currently in various stages of development, at the pre-clinical stage (in animal challenge efficacy studies). Vaccine peptides can elicit protection of animals from lethal viral (herpes simplex virus [HSV-1] and influenza A) infection or can block the progression of autoimmune diseases (e.g. rheumatoid arthritis as in the collagen induced arthritis (CIA] or experimental autoimmune myocarditis (EAM) models). L.E.A.P.S. technology is a novel T-cell immunization technology that enables the design and synthesis of non-recombinant, proprietary peptide immunogens. Combination of a small peptide that activates the immune system with another small peptide from a disease-related protein, thus a conjugate containing both an Immune Cell Binding Ligand (ICBL) and a disease specific epitope, which allows the L.E.A.P.S. vaccines to activate precursors to differentiate and become more mature cells that can initiate and direct appropriate T cell responses. As such, readily synthesized, defined immunogens can be prepared to different diseases and are likely to elicit protection or therapy as applicable in humans as they are in mice. L.E.A.P.S. vaccines have promise for the treatment of rheumatoid arthritis and other inflammatory diseases and for infections, such as influenza and HSV1. The protective responses are characterized as Th1 immune and immunomodulatory responses with increased IL-12p70 and IFN-γ (Th1 cytokines) but reduced inflammatory cytokines TNF-α, IL-1 and IL-17 (Th2 and Th17 cytokines) and concomitant changes in antibody subtypes. LEAPS immunogens have been used directly in vivo or as ex vivo activators of DC which are then administered to the host.",
keywords = "Antiviral vaccines, Autoimmunity, Cytokines, Dendritic cell, Immune response, Mode of action, Peptide, T cells, Vaccines",
author = "Zimmerman, {Daniel H.} and Harold Steiner and Roy Carmabula and Eyal Talor and Rosenthal, {Ken S.}",
year = "2012",
month = "9",
day = "1",
doi = "10.4172/2157-7560.1000149",
language = "English (US)",
volume = "3",
journal = "Journal of Vaccines and Vaccination",
issn = "2157-7560",
number = "5",

}

TY - JOUR

T1 - LEAPS therapeutic vaccines as antigen specific suppressors of inflammation in infectious and autoimmune diseases

AU - Zimmerman, Daniel H.

AU - Steiner, Harold

AU - Carmabula, Roy

AU - Talor, Eyal

AU - Rosenthal, Ken S.

PY - 2012/9/1

Y1 - 2012/9/1

N2 - The L.E.A.P.S.™ (Ligand Epitope Antigen Presentation System) technology platform has been used to develop immunoprotective and immunomodulating small peptide vaccines for infectious and autoimmune diseases. Several products are currently in various stages of development, at the pre-clinical stage (in animal challenge efficacy studies). Vaccine peptides can elicit protection of animals from lethal viral (herpes simplex virus [HSV-1] and influenza A) infection or can block the progression of autoimmune diseases (e.g. rheumatoid arthritis as in the collagen induced arthritis (CIA] or experimental autoimmune myocarditis (EAM) models). L.E.A.P.S. technology is a novel T-cell immunization technology that enables the design and synthesis of non-recombinant, proprietary peptide immunogens. Combination of a small peptide that activates the immune system with another small peptide from a disease-related protein, thus a conjugate containing both an Immune Cell Binding Ligand (ICBL) and a disease specific epitope, which allows the L.E.A.P.S. vaccines to activate precursors to differentiate and become more mature cells that can initiate and direct appropriate T cell responses. As such, readily synthesized, defined immunogens can be prepared to different diseases and are likely to elicit protection or therapy as applicable in humans as they are in mice. L.E.A.P.S. vaccines have promise for the treatment of rheumatoid arthritis and other inflammatory diseases and for infections, such as influenza and HSV1. The protective responses are characterized as Th1 immune and immunomodulatory responses with increased IL-12p70 and IFN-γ (Th1 cytokines) but reduced inflammatory cytokines TNF-α, IL-1 and IL-17 (Th2 and Th17 cytokines) and concomitant changes in antibody subtypes. LEAPS immunogens have been used directly in vivo or as ex vivo activators of DC which are then administered to the host.

AB - The L.E.A.P.S.™ (Ligand Epitope Antigen Presentation System) technology platform has been used to develop immunoprotective and immunomodulating small peptide vaccines for infectious and autoimmune diseases. Several products are currently in various stages of development, at the pre-clinical stage (in animal challenge efficacy studies). Vaccine peptides can elicit protection of animals from lethal viral (herpes simplex virus [HSV-1] and influenza A) infection or can block the progression of autoimmune diseases (e.g. rheumatoid arthritis as in the collagen induced arthritis (CIA] or experimental autoimmune myocarditis (EAM) models). L.E.A.P.S. technology is a novel T-cell immunization technology that enables the design and synthesis of non-recombinant, proprietary peptide immunogens. Combination of a small peptide that activates the immune system with another small peptide from a disease-related protein, thus a conjugate containing both an Immune Cell Binding Ligand (ICBL) and a disease specific epitope, which allows the L.E.A.P.S. vaccines to activate precursors to differentiate and become more mature cells that can initiate and direct appropriate T cell responses. As such, readily synthesized, defined immunogens can be prepared to different diseases and are likely to elicit protection or therapy as applicable in humans as they are in mice. L.E.A.P.S. vaccines have promise for the treatment of rheumatoid arthritis and other inflammatory diseases and for infections, such as influenza and HSV1. The protective responses are characterized as Th1 immune and immunomodulatory responses with increased IL-12p70 and IFN-γ (Th1 cytokines) but reduced inflammatory cytokines TNF-α, IL-1 and IL-17 (Th2 and Th17 cytokines) and concomitant changes in antibody subtypes. LEAPS immunogens have been used directly in vivo or as ex vivo activators of DC which are then administered to the host.

KW - Antiviral vaccines

KW - Autoimmunity

KW - Cytokines

KW - Dendritic cell

KW - Immune response

KW - Mode of action

KW - Peptide

KW - T cells

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=84879644138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879644138&partnerID=8YFLogxK

U2 - 10.4172/2157-7560.1000149

DO - 10.4172/2157-7560.1000149

M3 - Article

AN - SCOPUS:84879644138

VL - 3

JO - Journal of Vaccines and Vaccination

JF - Journal of Vaccines and Vaccination

SN - 2157-7560

IS - 5

ER -